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Abstract 
Multifunctional nanomaterials combining diagnosis and therapeutic properties have attracted a 
considerable attention in cancer research. Yet some important challenges are still to be faced, including 
an optimal coupling between these two types of properties that would be effective within complex 
biological tissues.  To address these points, we have prepared novel nanoplatforms associating controlled 
drug delivery of doxorubicin and Magnetic Resonance Imaging (MRI) contrast-enhancement that exhibit 
high specificity towards cancer cells compared to normal cells and evaluated them both in 2D cultures 
and within 3D tissue-like biomimetic matrices.  
Methods: Nanoplatforms were prepared from hollow silica nanoparticles coated with MnO2 nanosheets 
and conjugated with the AS1411 aptamer as a targeting agent. They were fully characterized from a 
chemical and structural point of view as well as for drug release and MRI signal enhancement.  Standard 
two-dimensional monolayer cultures were performed using HeLa and Normal Human Dermal 
Fibroblasts (NHDF) cells to testify targeting and cytotoxicity. Cellularized type I collagen-based hydrogels 
were also used to study nanoparticles behavior in 3D biomimetic environments. 
Results: The as-established nanoplatforms can enter HeLa cells, leading to the dissociation of the MnO2 
nanosheets into Mn2+ that enhanced T1 magnetic resonance signals and concomitantly release 
doxorubicin, both effects being markedly more significant than in the presence of NHDFs. Moreover, 
particles functionality and specificity were preserved when the cells were immobilized within type I 
collagen-based fibrillar hydrogels.  
Conclusion: The use of MnO2 nanosheets as glutathione-sensitive coatings of drug loaded nanoparticles 
together with surface conjugation with a targeting aptamer offers an effective strategy to obtain efficient 
and specific nanotheranostic systems for cancer research, both in 2D and 3D. The here-described 
tissue-like models should be easy to implement and could constitute an interesting intermediate 
validation step for newly-developed theranostic nanoparticles before in vivo evaluation. 
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Introduction 
Despite the rapid improvement of modern 
medicine, the early diagnosis and therapy of cancer is 
still a challenge. The continuous development of 
nanotechnology and the emergence of targeted 
treatments provide an inequivalent opportunity in 
this area. The past decade has witnessed the 
engineering of many theranostic nanosystems, where 
the integration of different imaging agents and 
therapeutic drugs into a single nanoparticle (NP) has 
made it possible to exhibit multiple functionalities 
[1-4]. Extensive efforts have also allowed for the 
identification of active targeting reagents, such as folic 
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acid, hyaluronic acid, aptamers, or transferrin, that 
bind with high specificity to the cancerous cell 
membrane [5-8]. At the same time, strategies were 
developed to achieve a controlled drug release 
triggered by intrinsic physiological microenvi-
ronment changes (pH, redox, enzyme, heat, etc.) 
and/or external stimuli (including light, 
magnetic/electric field, ultrasound, etc.) [9-11]. All 
those developments taken together, it becomes 
possible to simultaneously reduce the side-effects of 
anticancer agents to normal tissues and enhance their 
therapeutic efficiency [12]. Indeed, there still is some 
room for large improvement, in terms of drug loading 
and targeting efficiency. 
 From an imaging perspective, signals of most 
previously-reported nanosystems are “always on” 
regardless of the absence or presence of the target 
cells, resulting in a low contrast detection [13]. Among 
available nanoparticles, Mesoporous Silica 
Nanoparticles (MSNs) have been widely considered 
for the delivery of anticancer drugs [11,14,15]. To 
tackle MSNs intrinsic limited loading capacity, 
Hollow MSNs (HMSNs) with rattle or hollow 
structure have been prepared as they can efficiently 
accommodate drugs not only into mesoporous 
channels of their shell but also within their internal 
cavity [16-18]. Moreover, recent progress in the design 
of gated HMSNs has shown some promise in the 
development of controlled-release theranostic 
nanosystems. Different “gatekeepers”, such as 
organic molecules, biomacromolecules and 
nanoparticles, have been used, allowing pore-opening 
under the stimulation of pH change, temperature, 
nucleotides, antibodies, enzymes, glucose, or 
photoirradiation [19-21]. However, these gated 
nanosystems usually require a highly-sophisticated 
design that has a strong impact on synthesis time and 
development cost, ultimately hindering their transfer 
to the market, despite their demonstrated 
functionality.  
 Recently, MnO2 nanosheets, a 2D ultrathin 
semiconductor material with wide applications in the 
energy field [22], has attracted large attention as a 
gatekeeper for drug nanocarriers [23-25]. They exhibit 
a broad and intense absorption band at around 374 
nm, making MnO2 nanosheets an efficient 
broad-spectrum quencher [26]. Moreover, MnO2 can 
be converted to Mn2+ via reduction by endogenous 
glutathione (GSH), leading to decomposition of the 
MnO2 nanosheets [27]. While manganese(IV) ions in 
the nanosheets are shielded from water due to their 
6-fold coordination with oxygen atoms, free solvated 
Mn(II) ions are efficient T1 contrast agents for 
Magnetic Resonance Imaging (MRI) [28]. GSH is an 
essential endogenous antioxidant that has many 
cellular functions and high GSH levels are implicated 
in many diseases typically associated with cancer, 
liver damage, or heart problems [29]. Therefore, much 
attention has been paid to the use of GSH to design 
intracellular controlled release systems [30]. In 
addition, whereas the extracellular pH of normal 
tissues and blood is constant at 7.4, the measured 
extracellular values of most solid tumors range from 
pH 6.5 to 7.2, such lower pH values being more 
favorable for the reaction between MnO2 and GSH 
[31]. Based on this principle, several 
MnO2@SiO2-based controlled-release nanosystems 
with GSH-induced contrast-enhanced magnetic 
resonance signal have already been described [23, 
32,33]. However, none of them took advantage of the 
specificity of HMSNs so far.  
 Another key challenge in this area lies in the 
precise control of the drug release using 
stimuli-responsive systems. Thus, tumor 
microenvironment, that has a crucial role in cancer 
progression, exhibit several specific biological and 
physico-chemical features that can be exploited to 
trigger the drug release at the tumor site [34]. 
However, the efficiency and stimulation of 
nanosystems are often tested in two-dimensional (2D) 
systems, in which seeded cancer cells do not 
experience the real microenvironment they find in 
vivo, where physiological fluids, tissues as well as 
interactions between cancer and stromal cells may 
impair the drug delivery or its functionality. The 
transfer from 2D data to in vivo during preclinical 
studies may therefore be extremely time-consuming 
and costly. Therefore, the design of three-dimensional 
(3D) environments exhibiting some features of in vivo 
tumors, such as three-dimensional architecture, 
cell-cell interaction and hypoxia should provide 
highly useful tumor tissue in vitro models for testing 
anticancer therapeutics [35,36]. In this context, the use 
of type I collagen, the major protein in most animal 
tissues, to prepare biomimetic constructs is of 
particular relevance [37-39]. Most importantly, it has 
been shown that they could act as models to study the 
interactions between nanoparticles and cells in a 3D 
environment [40,41]. 
 Herein, we propose, for the first time, a novel 
and facile strategy for the fabrication of a 
multifunctional nanoprobe for contrast-enhanced 
bimodal cellular imaging and targeted therapy, as 
depicted in Figure 1. The nanoprobe consists of three 
components, including (1) doxorubicin(DOX)-loaded 
hollow mesoporous silica nanoparticles, (2) MnO2 
nanosheets that act as both gatekeeper for DOX 
release from HMSNs and contrast agent for MRI and 
(3) cancer cell-targeting aptamers (AS1411), that bind 
to nucleolin, a nucleolar phosphoprotein which is 
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overexpressed on the surface of certain cancer cells 
[28, 42, 43]. We demonstrate that this multifunctional 
HMSNs@MnO2(DOX)/apt theranostic nanosystem 
exhibits a synergistic delivery/imaging effect in 
standard 2D conditions. We also show that the 
functionality and specificity of these nanoplatforms 
are preserved within 3D cellularized collagen 
hydrogels, that can be useful biomimetic models for 
evaluating nanotheranostic systems performance 
before in vivo studies.   
Methods 
Materials and reagents 
 All chemical reagents were analytical grade and 
used without further purification. Cetyltrimethyla-
mmonium bromide (CTAB), tetraethyl orthosilicate 
(TEOS), sodium carbonate (Na2CO3), absolute 
ethanol, concentrated hydrochloric acid, ammonium 
aqueous solution (25-28%), triethanolamine (TEA), 
3-Triethoxysilylpropylamine (APTES), potassium 
permanganate (KMnO4), 2-(N-Morpholino)ethane-
sulfonic acid hydrate (MES), doxorubicin 
hydrochloride (DOX) and fluorescein isothiocyanate 
(FITC) were purchased from Sigma-Aldrich. MilliQ 
water (18 MΩ, Millipore, France) was used for the 
preparation of the solutions and for all rinses. 
4,6-diamidino-2-phenylindole (DAPI). Fetal bovine 
serum, Dulbecco’s Modified Eagle’s Medium 
(DMEM), trypsin, glutamine, penicillin-streptomycin 
solution and AS1411 aptamer (5′-NH2-GGTGGTGGT
GGTTGTGGTGGTGGTGG-3′) were purchased from 
ThermoFisher.  
Preparation of HMSNs@MnO2/apt  
 Bare HMSNs were prepared using previously 
reported methods [44,45]. To functionalize the particle 
surface with amine groups, as-synthesized HMSNs 
were first dispersed in 20 mL of toluene, followed by 
addition of 1 mL of APTES. The system was sealed 
and refluxed at 120 °C in oil bath for 12 h. Afterward, 
the mixture was centrifuged and washed with ethanol 
for several times to remove the residual APTES. Then, 
20 mg of HMSNs-NH2 was dispersed in 4.2 mL MES 
buffer (0.1M, pH 6.0) and then 0.8 mL of 5 mM 
KMnO4 in water was added to the mixture under 
ultrasonic condition. The resulting mixture was 
sonicated for another one hour during which 
brown-black colloids were observed. Subsequently, 
the raw product was collected by centrifugation, 
washed several times with deionized water and 
alcohol to remove any possible residual reactants, and 
redispersed in 2 mL PBS solution (pH 7.4). The 
physical adsorption of aptamer on HMSNs@MnO2 
was carried out by mixing 0.8 mL of HMSNs@MnO2 
(20 mg/mL) in PBS and 200 µL of AS1411 (1 µM). 
After 3 h of incubation, the solution was centrifuged 
at 6000 rpm, washed several times, and then 
dispersed in PBS (pH 7.4) for further application. Full 
protocol is available in Supplementary Material. The 
preparation of fluorescently-labeled hollow 
mesoporous silica nanoparticles was performed by 
adding FITC to the starting solution used for bare 
HSMNs preparation.  
Particles characterization  
 Transmission Electron Microscopy (TEM) 
studies were performed on a FEI Tecnai G2 Spirit 
microscope operating at 120 kV. Scanning electron 
microscopy (SEM) images were obtained on a Hitachi 
S-3400N scanning electron microscope with a field 
emission electron gun. Nitrogen sorption-desorption 
 
Figure 1. Schematic illustration of the preparation of HMSN@MnO2(DOX)/apt and the drug release mechanism. 
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isotherms were measured at 77 K with a 
Micromeritics ASAP2010 analyzer. Fluorescence 
images were recorded on a LEICA microscope. 
Dynamic Light Scattering (DLS) was used to 
determine the hydrodynamic diameter of the 
nanoparticles in Milli-Q water or in culture medium 
with Mastersizer 3000 Particle Size Analyzer. The 
reading was carried out at an angle of 90° to the 
incident beam (632 nm). The Contin algorithm was 
used to analyze the autocorrelation functions. X-ray 
Photoelectron Spectroscopy (XPS) analyses were 
performed with a PHOIBOS 100 spectrometer from 
SPECS GmbH. Inductively Coupled Plasma Mass 
Spectrometry (ICP-MS) was used to determine the Mn 
content of the nanoparticles. 
Drug loading and release in vitro 
 10 mg of HMSNs@MnO2 nanoparticles were 
mixed with 1.5 mg of DOX in 1.5 mL of PBS/DMSO 
(1:1) mixture solution and then stirred under dark 
conditions for 24 h. Subsequently, the product was 
collected by centrifugation and washed several times 
with PBS to remove the free DOX. Then 100 µL of 
AS1411 (1 µM) in PBS was added, and after 3 h of 
stirring, the resulting HMSNs@MnO2(DOX)/apt 
nanoparticles were collected by centrifugation and 
re-dispersed in PBS solution for subsequent use. To 
evaluate the DOX loading, the remaining DOX 
molecules in the supernatant solutions were 
determined by fluorescence spectroscopy (λex= 500 
nm, λem = 590 nm). The loading of the nanoparticles 
was expressed as the mass percentage of DOX with 
respect to the total mass of HMSNs@MnO2(DOX)/apt 
nanoparticles.  
 In vitro DOX release from the 
HMSNs@MnO2(DOX)/apt nanoparticles was studied 
in PBS buffer in absence or presence of GSH at pH 
values of 7.4 and 5.5. For each release study, 1.0 mL of 
DOX-loaded nanoparticles (1.0 mg.mL-1) were 
dispersed inside a dialysis bag that was soaked in 9.0 
mL PBS and shaken at room temperature. At selected 
time intervals, the sample was collected and 2 mL of 
solution outside the dialysis bag was removed. Then, 
2 mL of fresh PBS buffer was added.  The removed 
solution was properly diluted and the amount of DOX 
molecules present was measured by fluorescence 
spectroscopy. The same amount of the DOX solution 
was introduced in the dialysis bag and its diffusion 
kinetics was used as control for drug release studies.  
Cell culture 
 Normal Human Dermal Fibroblasts (NHDF) 
and HeLa cells were cultured in complete cell culture 
medium (DMEM with GlutaMAX™, without phenol 
red supplement, with 10% fetal serum, 100 U.mL-1 
penicillin, 100 μg.mL-1 streptomycin). Tissue culture 
flasks (75 cm2) were kept at 37 °C in a 95% air: 5% CO2 
atmosphere. Before confluence, the cells were 
removed from culture flasks by treatment with 0.1% 
trypsin and 0.02% EDTA. Cells were rinsed and 
resuspended in the above culture medium before use. 
In vitro cytotoxicity assays 
 First, HeLa were seeded in a 24-well plate at a 
density of ~5×104 cells/well overnight to allow cell 
attachment onto the surface of the wells. Then, 0.5 mL 
of fresh medium containing various concentrations of 
HMSNs@MnO2(DOX)/apt was added into the wells. 
After incubation for 24 h, cell activity was evaluated 
by the Alamar Blue assay. Control experiments were 
performed by incubating HeLa cells with free DOX 
and HMSNs@MnO2(DOX) at various drug contents or 
HMSNs@MnO2(DOX)/apt at equivalent particle 
concentration for 24 h. To confirm the cytotoxicity of 
DOX released from the nanoplatform under GSH, 
similar control experiments were performed with 
NHDF cells incubated in presence of 5 mM GSH. 
Cell uptake studies by fluorescence imaging  
 NHDFs and HeLa cells were seeded in a round 
glass disk that was inserted in 24-well plate (~5×104 
cells per well) and cultured for 24 h. The cell medium 
was removed, and then cells were incubated with 0.5 
mL of fresh cell medium containing FITC-labeled 
HMSNs@MnO2(DOX)/apt nanoparticles for another 
12 h.  After medium removal, the cells were washed 
with PBS for several times, and then 0.5 mL of fresh 
cell medium with or without 5 mM GSH was added 
and incubated for another 3 hours. Fixation of the cells 
was carried out using 4% (v/v) paraformaldehyde 
(PFA) for 2 h and rinsed three times using PBS. After 
washing, cellular nuclei were stained with 1% (v/v) 
solution of DAPI in PBS buffer for 20 min and washed 
with PBS three times. Last, cell imaging was carried 
out by fluorescence microscopy. For the HeLa cells 
imaging, the procedure was similar, except that 
HMSNs@MnO2(DOX) or HMSNs@MnO2(DOX)/apt 
particles were added and no GSH treatment was 
performed.  
Measurement of MRI relaxation properties 
 Imaging of MRI phantoms measurement was 
performed with a Bruker Avance III HD 300 
spectrometer, equipped with a 10 mm micro imaging 
probe, having a maximum gradient capacity of 3 T.m-1 
in the x, y and z directions. The Multi Slice Multi Echo 
(MSME) pulse sequence was used, acquiring 1 echo 
but 8 slices with a slice thickness of 1 mm. The size of 
the images was: 128×128 with a Field of View of 
9.5×9.5 mm, resulting in a voxel size of 74×74 µm. 
Images were acquired with 1 scan and T1 weighting 
Nanotheranostics 2018, Vol. 2 
 
http://www.ntno.org 
407 
was obtained by using a short repetition time (TR) of 
200 ms and using the shortest possible echo time (TE), 
namely 4.92 ms, in order to minimize the effect of T2 
relaxation. 
Preparation of 3D collagen-based tumor 
models 
 Type I collagen was purified from rat tails and 
the final concentration was estimated by 
hydroxyproline titration, as previously described [37]. 
Tubes separately filled with collagen solution (2 
mg.mL-1 in 17 mM acetic acid), whole cell culture 
medium, and 0.1 M NaOH were kept in ice bathes for 
1 h before preparation to slow down the gelling 
kinetics of collagen. First, 500 μL of collagen solution 
and 400 μL of culture medium were added to a 1.5 mL 
tube and vortexed vigorously. After addition of 30 μL 
of 0.1 M NaOH and strong vortexing, 125 μL of the 
NHDF or HeLa cell suspension at a density of 106 
cells/mL was added and mixed homogeneously. 
Then 0.9 mL was sampled from the mixture and 
deposited into a 24-well plate. The plate was then 
incubated at room temperature for 10 min for 
complete gelling of collagen.  
Cytotoxicity and functionality within 3D 
models 
 Two sets of experiments were designed [41]. In a 
first approach, selected particles were introduced in 
the cell suspension prior to their addition to the 
collagen solution, at a final concentration of 100 
µg.mL-1. Then collagen gels were formed by pH 
increase to 7. After 48 h of incubation, the cell viability 
was assessed in the same way as for 2D tests except 
that 800 μL of water were first added to the collagen 
gel, left for 0.5 h at room temperature in order to 
extract the Alamar Blue solution trapped in the gel, 
and then collected for the absorbance measurements. 
Particle internalization was also studied in the same 
configuration. For this, after the 48 h incubation 
period, the gels were rinsed 3 times with PBS and 
fixed with 4% paraformaldehyde overnight. Next, the 
fixed samples were dehydrated in ethanol and 
butanol, and incorporated in paraffin to be able to 
obtain 10 μm histological sections with a manual 
microtome. Before observation, the as-obtained 
samples were immersed in toluene, ethanol, and then 
water for rehydration. The cell nuclei were stained 
with DAPI for 10 min and rinsed with PBS before 
observation. The second approach consisted in adding 
1.0 mL of a 0.2 mg.mL-1 suspension of the 
HMSNs@MnO2(DOX)/apt particles onto the surface 
of particle-free cellularized collagen gels. After 3 
hours of contact, the MR imaging experiments were 
performed as described above. 
Statistical Analysis 
 Graphical results are presented as mean ± SD 
(standard deviation). Statistical significance was 
assessed using one-way analysis of variance 
(ANOVA) followed by Tukey (compare all pairs of 
groups) or Dunnett (compare a control group with 
other groups) post-hoc test. The level of significance 
in all statistical analyses was set at a probability of P < 
0.05. 
Results and discussion 
Preparation and characterization of the 
nanoplatforms 
 The HMSN@MnO2/apt nanoparticles were 
prepared according to the process depicted in Figure 
1. In brief, monodisperse solid SiO2 nanoparticles 
(sSiO2) were first prepared using a modified Stöber 
method. The prepared sSiO2 were then coated with a 
CTAB/SiO2 shell via base-catalyzed hydrolysis of 
TEOS and condensation of silica onto the surface of 
CTAB pre-coated sSiO2. The resulting 
sSiO2@CTAB/SiO2 particles were simultaneously 
treated with Na2CO3 to remove sSiO2, and NH4NO3 to 
remove CTAB, resulting in HMSNs with hollow cores 
and penetrating pore channels [44]. APTES was 
grafted on the surface of nanoparticles to get 
HMSN-NH2. Finally, ultrathin MnO2 nanosheets were 
formed onto the surface of HMSN-NH2 thanks to the 
reaction with MES and KMnO4 to obtain 
HMSN@MnO2. DOX was then loaded inside or on the 
surface of the nanoparticles by the impregnation 
scheme described above. To end, AS1411 aptamers 
were attached on the surface of MnO2 nanosheets 
thanks to nucleobase-mediated physisorption [28].  
 As shown in the TEM image of Figure 2a, the 
prepared hollow mesoporous HMSN nanoparticles 
exhibit a uniform diameter of ~140 nm and form a 
colorless well-dispersed suspension in deionized 
water (DI) (Figure 2d). The diameter measured by 
DLS, Dm, is about 200 nm in DI, which is slightly 
larger than the TEM data and may reflect some 
aggregation (Table 1). The contrast between shell and 
core of the silica nanospheres confirms their hollow 
structure. The shell of the HMSN with a thickness of 
~25 nm displays an obvious mesoporous silica 
structure generated by the removal of pore templates. 
In DI water, the obtained HMSNs exhibited a negative 
zeta potential ζ of -18.4 mV, as expected for silica 
surfaces (Table 1). 
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Table 1. Mean diameter Dm from DLS with corresponding 
polydispersity index (PDI) and Zeta potential ζ in deionized water  
Sample Dm DLS (nm) PDI ζ (mV) 
HMSNs 200 ± 18 0.254 -18.4 ± 0.5 
HMSNs-NH2 256 ± 27 0.317 +10.4 ± 0.3 
HMSNs@MnO2 319 ± 41 0.579 -15.4 ± 0.2 
HMSNs@MnO2(DOX) 316 ± 26 0.500 -7.3 ± 0.8 
HMSNs@MnO2(DOX)/apt 248 ± 15 0.279 -16.1 ± 0.3 
 
 
 The N2 adsorption-desorption isotherm of the 
HMSN showed a typical type IV curve of 
surfactant-assisted mesoporous silica with a double 
strong and sharp adsorption step at intermediate 
relative partial pressure values around 0.4 (Figure S1). 
This feature is associated with nitrogen condensation 
inside the mesopores by capillarity. The application of 
the Brunauer-Emmett-Teller (BET) model resulted in 
a high value for the specific surface of 840 m2.g-1.  In 
parallel, the Barrett-Joyner-Halenda (BJH) model 
applied on the adsorption branch of the isotherms led 
to an average pore diameter of 3.89 nm (Figure S1). 
The absence of a hysteresis loop in this interval of 
P/P0, as well as the narrow BJH pore size distribution, 
also suggested the existence of uniform cylindrical 
channels throughout the material.  
 The successful surface functionalization of the 
hollow mesoporous silica nanoparticles using APTES 
could be checked by the increase of the zeta potential 
that reached a positive value (+10.4 mV) (Table 1). 
Upon contact of these HMSN-NH2 particles with MES 
and KMnO4, a visual color change from white to 
brown was observed (Figure 2e). After extensive 
washing, UV-vis spectra clearly evidenced a strong 
absorption band at 400 nm, that can be attributed to 
the MnO2 nanosheets, whose intensity increase with 
the initial KMnO4 concentration (Figure S2). The 
formation of composite nanoparticles (HMSN@MnO2) 
with a rough capping layer was confirmed by TEM 
images (Figure 2b). Moreover, the average diameter of 
HMSN@MnO2 was changed from 200 nm to ca. 320 
nm, accompanied by a polydispersity index (PDI) 
increase from 0.254 to 0.579, which suggests that the 
MnO2 coating induces a slight tendency for the 
particles to aggregate. The zeta potential of 
nanoparticles was also modified, from +10.4 mV 
down to -15.4 mV after functionalization, in 
agreement with values in the literature [46]. After 
coating, FTIR spectra also evidenced a peak at 1413 
cm-1 characteristic of Mn-O vibrations in MnO2 
(Figure S3). Sorption isotherms also confirmed the 
coating of the nanoparticles. HMSN@MnO2 presented 
flat sorption curves when compared to those of 
HMSN (at P / P0 = 0.4) (Figure S1), thus indicating a 
significant pore blocking. Nonetheless, HMSN@MnO2 
showed an additional inflection at P/P0 > 0.8, that can 
correspond to secondary macropores resulting from 
the MnO2 capping layer with rough surface. 
HMSN@MnO2 showed a weak peak at pore diameter 
of 2.35 nm, confirming the partial pore blocking effect 
of the MnO2 capping layer. Finally, when 
HMSN@MnO2 were put in contact with GSH (10 mM), 
the color of the suspension changed back from brown 
to white, indicative of the disappearance of the MnO2 
layer (Figure 2f). TEM images clearly confirmed the 
regeneration of the smooth surface and clear 
mesoporous structure of HMSN (Figure 2c).  
 
 
Figure 2. TEM images of (a) HMSNs, (b) HMSN@MnO2/apt, (c) HMSN@MnO2/apt after GSH treatment and the corresponding digital images from left to right (d, 
e, f).  
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 DOX was then selected as a guest molecule to 
confer anticancer properties to the nanoparticles. The 
loading was performed by a simple impregnation 
route in a mixed aqueous/organic medium. The 
resulting DOX-loaded HMSN@MnO2 particles had a 
size distribution similar to unloaded particles but the 
zeta potential changed from -15.4 mV to -7.3 mV, 
suggesting that at least part of the drug is adsorbed on 
the MnO2 coating.  The UV-vis spectra of the loaded 
particles showed an additional absorption band at ca. 
480 nm similar to the one of DOX (Figure S2) and two 
peaks at 1624 cm-1 and 1580 cm-1 belonging to the 
benzene ring structure of DOX could be observed on 
the FTIR spectra of the HMSNs@MnO2(DOX) sample 
(Figure S3). The DOX loading of HMSN@MnO2, as 
estimated by fluorescent emission measurements of 
the supernatant after impregnation, reached ca. 80 
µg.mg-1.   
 As a final step, the anti-nucleolin AS1411 was 
adsorbed on the HMSNs@MnO2(DOX) particles 
which resulted in a significant decrease in the average 
particle diameter and of the PDI (Table 1). This can be 
correlated with the more negative value of the zeta 
potential (from -7.6 mV without aptamer to -16.1 mV 
after AS1411 adsorption), that results in an enhanced 
particle colloidal stability thanks to electrostatic 
repulsion. FTIR spectra showed an additional peak at 
1742 cm-1 that can correspond to the C=O stretching 
vibration of the aptamer (Figure S3).  
 To characterize the chemical compositions of the 
final HMSNs@MnO2(DOX)/apt nanoparticles, their 
element composition was determined by XPS (Figure 
3a). Mn, Si, C, O and N peaks were observed. Indeed, 
considering that the analysis depth of XPS analysis is 
10 nm at maximum, it only probes the outer surface of 
the particles. It is therefore not surprising that the Si 
At% is rather low (19.8 %), corresponding to ca. 60 
wt% of SiO2. In contrast, the contribution of organic 
molecules (DOX and AS1411) (> 35 % C) is enhanced 
compared to the whole particle volume. The Mn 
relative amount is 0.9 At% corresponding to ca. 5 wt % 
MnO2. Considering that manganese oxide nanosheets 
have been reported to be ca. 1 nm thick, a ca. 10 wt % 
amount would have been expected, suggesting that 
 
Figure 3. XPS analysis of the HMSNs@MnO2(DOX)/apt nanoparticles: (a) full XPS spectrum with atomic analysis and deconvoluted signals with proposed 
attributions at the (b) Mn2p, (c) Si2p and (d) O1s levels. 
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the MnO2 coating is not homogeneous over the whole 
particle surface. At the Mn2p level (Figure 3b), the two 
peaks at 642 eV and 653.8 eV unambiguously sign for 
the presence of MnO2, as also confirmed by the peak 
at 530.1 eV on the O1s spectrum [47] (Figure 3d). The 
peaks at 103.2 eV on the Si2p spectrum (Figure 3c) and 
532.4 eV on the O1s spectrum are characteristic of 
hydrated silica [48]. Deconvoluted spectra at the C1s 
and N1s levels evidenced the presence of C-C, C-O, 
C=O, C-N and N-C=O groups (Figure S4). The latter is 
a clear indication of the presence of the aptamer on 
the particle surface [49], while the others can belong to 
both AS1411 and DOX. 
Drug release and MRI imaging properties of 
the nanoplatforms 
 The feasibility of MnO2 degradation when 
treated with GSH and pH was first investigated. As 
shown in the Figure S5, the HMSNs@MnO2/apt 
nanoplatforms were stable at neutral pH but, after 
interaction with GSH, the color of the system quickly 
changed from brown to colorless, with a more 
pronounced effect when GSH concentration was 
increased from 5 mM to 10 mM. Acidic pH slightly 
destabilized the nanoplatform, due to the intrinsic 
instability of MnO2 in these conditions.  
 These observations were quantitatively assessed 
by monitoring DOX release in different conditions 
(Figure 4). In the absence of GSH, the DOX release 
was less than 10 % over 50 h at pH 7.4. When the 
MnO2 coating was destabilized, either in acidic 
conditions or by addition of GSH at neutral pH, ca. 20 
% of the DOX content was released within 10 h and 
then a slower release, up to ca. 35-40 %, occurred in 
the next 40 h. When GSH was added in acidic 
conditions, the shape of the release curve was quite 
similar (i.e. fast release during 10 h followed by 
slower release) but the amount of released DOX at the 
end of the first phase was much higher (ca. 50 %) than 
in the two previous conditions and the total release 
after 50 h was larger than 60 %. As pointed out earlier, 
DOX molecules may be located on the MnO2 surface, 
inside the porous silica shell and within the particle 
empty core. Assuming that the GSH-free neutral pH 
conditions induce no significant dissolution of the 
MnO2 nanosheets, then the measured low release (less 
than 10 % of the initial dose) should correspond to 
surface-adsorbed DOX molecules. Upon GSH 
addition or acidification, much more DOX molecules 
are released following a two-step process. It is worth 
emphasizing that silica nanoparticles are less soluble 
in acidic than in neutral pH conditions and not 
sensitive to GSH unless specifically modified [50]. 
Thus it can be suggested that the first step 
corresponds to the release of DOX molecules both 
adsorbed on the surface and trapped in the porous 
shell due to the MnO2 coating dissolution, while the 
second one would sign for the slow diffusion of the 
drug located within the particles.  However, when 
both acidic conditions and GSH addition are 
combined, the overall release profile, and especially 
the duration of the fast-release period, is not 
significantly modified but more DOX is initially 
released. This may be interpreted considering that, in 
these conditions, the MnO2 
degradation is efficient enough to 
uncap all pores before diffusion of 
DOX molecules from the inside of 
the particle starts. In contrast, in 
GSH-only or acidic pH-only 
conditions, the MnO2 degradation 
process is less efficient and only part 
of the pores are uncapped before 
diffusion from the inside 
compartment becomes effective.  
This points out that the combination 
of reductive conditions due to GSH 
presence and acidic media where 
MnO2 is less stable is the most 
favorable for DOX release. 
 Because the reduction of MnO2 
by intracellular GSH could produce 
a large amount of Mn2+, which are 
efficient T1 contrast agents, the 
nanoplatform could also afford 
GSH/pH-activated detection by 
MRI. To verify this hypothesis, 
 
Figure 4. Cumulative release of the HMSNs@MnO2(DOX)/apt in different conditions: (blue) pH 7.4, 
(black) pH 5.5, (green) pH 7.4+ 5 mM GSH, (red) pH 5.5 + 5 mM GSH. Control samples: (pink) free DOX 
diffusion from dialysis bag and (pale green) uncoated HSMNs(DOX) in PBS solution (pH =7.4).  
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T1-weighted MR images of HMSN@MnO2/apt 
aqueous suspensions under different conditions were 
first performed. As shown in Figure 5a, the MRI 
signal of the HMSN@MnO2/apt sample in PBS at pH 
7.4 didn’t exhibit an obvious T1-MRI signal difference 
compared to that of deionized water. A significant 
T1-MRI signal enhancement could be observed at pH 
5.5. Adding 5 mM GSH in neutral and then acidic 
conditions further improved the T1-MRI signal 
intensity. The r1 relaxivity of the nanoplatform 
suspensions was also measured (Figure 5b) for 
HMSN@MnO2/apt at pH 5.5 in the presence of GSH, 
reaching a value of 9.25 mM-1.s-1 which is remarkably 
higher than that of the GSH-free solution at pH 7.4 (r1 
= 1.68 mM-1.s-1). Importantly such r1 values are higher 
than those reported for other Mn-based nanocontrast 
agents (Mn3O4 nanoparticles, 8.26 mM−1.s−1; 
Mn-MSNs, 2.28 mM−1.s−1 and MnO nanoplates, 5.5 
mM−1.s−1) [51-53]. The above results suggest that the 
MnO2 nanosheets can efficiently be converted into 
Mn2+ in a mildly acidic/GSH environment, explaining 
the rapid enhancement of the longitudinal relaxation 
rate with concentration. In conclusion, 
HMSNs@MnO2/apt present a clear pH/GSH- 
responsive T1-MRI performance. 
 In a second step, it was necessary to check that 
the designed nanoplatforms could efficiently kill 
cancer cells while being safe for normal cells. First, it 
was checked that drug-free HMSNs@MnO2 
nanoparticles had no impact on HeLa cells viability 
after 24 h of contact, as monitored by the Alamar Blue 
test (Figure S6). Then the cytotoxic effect of 
HMSNs@MnO2(DOX) and HMSNs@MnO2(DOX)/apt 
particles on HeLa cells viability was studied with the 
same method and compared to free DOX at the same 
drug concentrations. As shown on Figure 6a, no 
significant difference in cytotoxicity between free and 
encapsulated drug could be observed, with a 
continuous decrease of HeLa cells activity with 
increasing DOX dose, down to ca. 50 % for the highest 
investigated drug dose (16 µg.mL-1). The presence of 
the aptamer had no influence either. In a step further, 
the effect of HMSNs@MnO2(DOX)/apt particles 
concentration on HeLa and NHDF cells was 
monitored (Figure 6b). In the 5-160 µg.mL-1 range, 
HMSNs@MnO2(DOX)/apt particles have no obvious 
impact on NHDF while they are toxic for HeLa cells 
(i.e. viability below 80 %) for particle concentrations of 
10 µg.mL-1 or more. Importantly, if GSH (5 mM) was 
present in the NHDF culture medium, then high 
cytotoxicity was also measured, confirming its ability 
to trigger DOX release.  
 To confirm this hypothesis, the internalization of 
the HMSNs@MnO2(DOX)/apt was studied. As 
shown in Figure 7a-d, accumulation of the 
nanoplatforms, visualized by the green fluorescence 
of encapsulated FITC, in contact or within the cells 
could be observed for NHDF, without or with GSH, 
and HeLa cells. In the latter case, bright green 
aggregates are located near the nuclei, which appear 
blue after DAPI staining, strongly supporting their 
intracellular localization. For this sample, 
colocalization of the nanoplatform (green signal) and 
the DOX molecules (red signal) is evidenced. 
Noticeably, when no aptamer was present on the 
surface, low particle accumulation was observed and 
no clear red signal could be imaged (Figure 7d). For 
NHDF cells without GSH, the red areas are hardly 
seen whereas they are more clearly visible/detectable 
when GSH was present. It is important to point out 
that MnO2 nanosheets have previously been shown to 
efficiently quench the fluorescence of dyes in the 
UV-visible range [54]. Thus the observation of red 
signals on the fluorescence images indicates that DOX 
is no longer interacting with the manganese oxide 
coating, probably because the MnO2 nanosheets were 
reduced to Mn2+ by GSH. Noticeably, in the case of 
HMSNs@MnO2(DOX)/apt interacting with HeLa, the 
strong co-localization of FITC and DOX inside the 
cells would suggest that the MnO2 layer has been 
degraded but that part of the drug remains inside the 
particles (Figure 7c). In sharp contrast, for 
HMSNs@MnO2(DOX)/apt interacting with NHDF in 
the presence of GSH, many particles visualized by 
monitoring the green fluorescence do not exhibit a red 
fluorescence (Figure 7b).  This can be attributed to the 
fact that the MnO2 layer is degraded by GSH leading 
to DOX release before the internalization process. 
While viability tests have evidenced NHDF cells 
death in these conditions (blue bars on Figure 6b), 
indicating that released drug could be uptaken, the 
dilution of DOX within the cytoplasm may lead to a 
low fluorescence intensity, precluding its detection. 
 Altogether, HMSNs@MnO2(DOX)/apt 
nanoplatforms have the ability to be internalized by 
HeLa cells with a clear benefit of the presence of the 
targeting aptamer on the efficiency of this process. 
After degradation of the MnO2 coating, that may be 
due to both acidic pH of the lysosome and enhanced 
GSH expression, the particles can thereby release 
DOX molecules at the vicinity of the nucleus, 
resulting in an efficient cancer cell killing. At the same 
time, the formation of Mn2+ ions should allow for the 
detection of the cancer tissue via T1-weighted MRI. 
Very importantly, our experiments also indicate that 
these nanoplatforms are safe for normal NHDF cells 
in the absence of GSH.  
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Figure 5.  (a) T1-weighted solution MR images of HMSN@MnO2/apt under different conditions. (i: H2O; ii: pH 7.4; iii: pH 5.5; iv: pH 7.4 + GSH 5 mM and v: pH  5.5 
+ GSH 5 mM) after incubation at 37 °C for 1 h. (b) 1/T1 versus Mn concentrations for HMSN@MnO2/apt at (black) pH 7.4 and (red) pH 5.5 + 5 mM GSH. 
 
Figure 6. (a) HeLa cell viability after incubation with DOX, HMSNs@MnO2(DOX) and HMSNs@MnO2(DOX)/apt for 24 h as a function of DOX dose. (b) Cell 
cytotoxicity of HMSNs@MnO2(DOX)/apt after 24 h of incubation with NHDF, HeLa and NHDF cells treated with GSH as a function of particle concentration. 
 
Figure 7. Fluorescent images of (a) NHDF cells incubated with HMSNs@MnO2(DOX)/apt nanoparticles, (b) NHDF cells incubated with HMSNs@MnO2(DOX)/apt 
nanoparticles and 5 mM GSH, (c) HeLa cells incubated with HMSNs@MnO2(DOX)/apt nanoparticles, (d) HeLa cells incubated with HMSNs@MnO2(DOX) 
nanoparticles.  
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Figure 8. (a) Viability of NHDF and HeLa cells within different types of 3D collagen/silica nanocomposites after 24 h of incubation. (b) SEM image of nanoparticles 
(red arrow) interacting with HeLa cells (white arrow) within collagen hydrogels. 
 
Functionality of nanoplatforms in 3D 
biomimetic collagen matrices 
 At this stage of similar studies, in vivo 
evaluations are usually undertaken using 
tumor-bearing animals. However, in this work, we 
chose instead to go deeper into the understanding of 
the impact of a 3D environment on the functionality of 
the nanoplatform, a point that was not previously 
assessed in the literature. For this we prepared type I 
collagen matrices in conditions compatible with cell 
immobilization and particle encapsulation or 
diffusion [40,41]. 
 To check whether the nanoparticles preserved 
their efficiency and selectivity as cancer cell killing 
agents, the viability of NHDF and HeLa cells 
co-encapsulated with HMSNs@MnO2, 
HMSNs@MnO2(DOX), and HMSNs@MnO2(DOX)/ 
apt at a dose of 100 μg.mL-1 within the collagen 
matrices was studied  (Figure 8a). After 24 h, 
compared to the control group, the unloaded 
HMSNs@MnO2/apt showed very little toxicity for 
both types of cells. After DOX-loading, the 
HMSNs@MnO2(DOX)/apt nanoparticles neither 
showed much effect the viability of NHDF cells but 
exhibited a clear cytotoxic effect on HeLa cells, that 
was independent of the presence of the aptamer on 
the surface. Importantly, the decrease of HeLa cell 
viability was more significant than in the 2D 
experiments (see Figure 6b above), suggesting that the 
confinement of the cells and particles within the 
matrices strongly favors their interaction. As a matter 
of fact, SEM imaging allowed for the observation of 
nanoparticle aggregates at the close vicinity of the 
HeLa cells (Figure 8b). In such conditions, our results 
suggest that it may be no longer necessary to 
specifically target the cells by using the AS1411 
aptamer.  
 Fluorescence imaging of the encapsulated HeLa 
cells also evidenced the co-localization of DOX with 
the nuclei-staining DAPI, signing for their successful 
internalization (Figure 9). However red fluorescence 
signals could also be visualized outside the cells, 
suggesting that some MnO2 degradation also 
occurred outside the cells.   
 Then, to evaluate whether such an ultrasensitive 
GSH-responsive is suitable for in vivo tumor imaging 
by magnetic resonance, another configuration was 
used where selected nanoparticles were placed onto 
cellularized collagen hydrogels and left to diffuse for 
3 h. As shown in Figure 10, a weak MRI signal was 
obtained for all samples prepared in the absence of 
HeLa cells or in the presence of NHDF cells, in 
agreement with the fluorescence image in Figure 9 
that suggested partial destabilization of the 
nanoplatforms in contact with the collagen network. 
While comparable results were obtained when the 
aptamer-free particles were added to HeLa cells, 
HMSNs@MnO2(DOX)/apt particles led to a 
significant enhancement of the intensity of 
T1-weighted images, that was increased when the 
initial particle concentration was increased. These 
results clearly demonstrate that the functionality and 
specificity of the HMSNs@MnO2(DOX)/apt 
nanoplatforms is preserved within the 3D models. 
Interestingly, in this configuration, particles are not 
initially confined at the proximity of the cells but must 
find their way through the collagen network and bind 
to the HeLa cells. This explains why, in contrast to the 
previous system, the presence of the aptamer does 
have a significant beneficial effect on the MRI signal. 
In these 3D models, determination of the r1 value is 
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difficult as it would require to determine the precise 
amount of HMSNs@MnO2(DOX)/apt that have 
diffused inside the matrices and interacted with the 
cells. However, when comparing Figure 5a and Figure 
10, it quite clear that the T1 relaxation time is lower in 
the matrix than in suspension and that the decreased 
stability of the nanoplatforms in the collagen gels 
ultimately impacts on its contrasting efficacy, i.e. its 
ability to differentiate safe and tumor tissues.  
Conclusion  
 As a conclusion, a multicomponent hybrid 
nanoplatform allowing for combined MRI 
contrast-enhanced imaging and targeted therapy 
through controlled drug delivery was designed, 
prepared and fully characterized in vitro in 2D and 3D 
configurations. Of particular importance is the fact 
that their high selectivity towards HeLa cancer cells 
compared to normal human cells was preserved when 
they were able to diffuse through cellularized 
biomimetic collagen hydrogels. This strongly suggests 
that such hydrogels, that are (i) simple to prepare, (ii) 
suitable for traditional cell biology studies, (iii) 
amenable to MRI measurements and (iv) can easily be 
implemented in terms of structure, composition and 
type of immobilized cells, should be useful for a 
preliminary screening of newly-developed 
nanotheranostics before entering in vivo studies that 
are time-consuming, costly and are raising increasing 
ethical and public concern. 
 
 
Figure 9. Fluorescent images of HeLa cells incubated with HMSNs@MnO2(DOX)/apt within a collagen hydrogel for 24 h, (a) bright field; (b) blue channel (DAPI); 
(c) red channel (DOX) and (d) merge. 
 
 
Figure 10. T1-weighted MR images of collagen gels (a) without cells, (b,c) with NHDF cells and (d-f) with HeLa cells after 3h diffusion of (b,d) 0.2 mg.mL-1 
HMSNs@MnO2(DOX) (c,e) 0.2 mg.mL-1  HMSNs@MnO2(DOX)/apt and (f) 0.4 mg.mL-1  HMSNs@MnO2(DOX)/apt. 
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